Boston Scientific (BSX) reachead $100.88 at the closing of the latest trading day, reflecting a +1.53% change compared to its last close.
Boston Scientific continues to successfully expand its operations across various geographies outside the United States.
Boston Scientific has the highest Composite Rating of 126 companies in the medical products industry. The post Medical Products Leader Tops These Early-Bird Buy Points appeared first on Investor's Business Daily.
In the closing of the recent trading day, Boston Scientific (BSX) stood at $102.67, denoting a +1.97% change from the preceding trading day.
Boston Scientific, with substantial operations in China and Europe, faces significant risks due to escalating global trade tensions in 2025.
Investors continue to be optimistic about BSX, courtesy of its international expansion efforts and WATCHMAN's performance.
BSX's shares rise on the back of its innovative product portfolio and impressive value-added acquisition. However, the unfavorable macroeconomic scenario is concerning.
Boston Scientific (BSX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Boston Scientific Corporation (NYSE:BSX ) TD Cowen 45th Annual Healthcare Conference March 4, 2025 9:10 AM ET Company Participants Dan Brennan - Chief Financial Officer Ken Stein - Chief Medical Officer Art Butcher - Executive Vice President, MedSurg and APAC Conference Call Participants Josh Jennings - TD Cowen Josh Jennings Good morning. I'm Josh Jennings from the TD Cowen Medical Devices research team, and joined by Brian Kennedy and Eric Anderson, and we're excited to kick off Day 2 of the 45th Annual TD Cowen Healthcare Conference and thrilled to have executives from the Boston Scientific management team joining us and spending time with us this week.
Boston Scientific inks a deal to acquire the remaining 90% stake in SoniVie Ltd.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.